Search

Search Constraints

You searched for: Author/Creator Stock, Wendy

Search Results

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

5. A multi‐institutional comparison of mitoxantrone, etoposide, and cytarabine vs high‐dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Issue 8 (8th May 2020)

6. Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study. Issue 1 (13th September 2016)

7. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (14th February 2014)

8. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Issue 7 (July 2014)

9. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Issue 6 (6th April 2020)

10. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (August 2020)